Replies to post #601759 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Nothing competes with DCVax that targets many hundreds of protein sites on the tumor. As somebody who claims to have a hard science background you should know that. Though I guess a social science layman like myself understands oncology more than the "jock!"

[Dr Bala]

OK. Remind me of this again in 15 years please.

[hoffmann6383]

Our competition just got covered by NBC News.

False. Competition means they have the goods to compete with us. They are in a phase 2 trial. The primary endpoint is 3 year OS. The trial is not close to being complete with recruitment. There is likely 6+ years before this company sniffs FDA approval. The recent news article pointed out that a phase 3 will be required. This brings the 6+ years to 15+ years.

On the other hand, NWBO will be submitting multiple applications for RA approval this year.

[dstock07734]

Who said it is our competition? Dr. Bosch said so or Dr. Liau made such a claim. It is just something you conjured up.

Dr. Liau told in the webinar that there are 62 GBM patients alive.

How many patients in the case of MiniVax have reach over five years? I suspect it is zero. Here is something you need to update. It is very hard to reach five years for GBM patients. That's why the meta-analysis on five-year survival of GBM patients is very rare. If you check the meta-analysis on three-year survival, there are a bunch.

https://www.clinicaltrials.gov/ct2/show/NCT03400917

I suggest you go back watching the CBS 60 min on using polio to treat GBM again. SurVaxM vaccine may follow the same track. It only looks very promising at the beginning.